Vibalogics Increases Capacity with additional 200 L Line for Virus Manufacturing

News
Published: 7 May 2020

GERMANY-based contract development and manufacturing organization (CDMO) Vibalogics has increased its single-use bioreactor and purification capacity with a new manufacturing line to meet increasing demand for its specialist oncolytic virus and viral vector manufacturing services.

The new manufacturing line will add to Vibalogics’ existing lines and features 50 L and 200 L single-use bioreactors and a Siemens process control system, further enhancing the company’s state-of-the-art offering within the field of GMP-compliant manufacturing of complex live biologicals.

To complement the new bioreactor, the company has also invested in an Äkta-ready chromatography system for downstream processing and liquid handling equipment to deal with the increased volumes involved in this scale of operation.

Operating from a multi-product BSL-2 facility in northern Germany, Vibalogics specializes in drug substance and drug product manufacturing of live virus and viral vectors for oncolytic virus, gene therapy, and vaccine products.

Dr. Stefan Beyer, managing director at Vibalogics said: “As a leading specialist in the aseptic processing of live biological products, we continue to increase our capacity and scale of operations in line with the growing global demand for these services and already have orders in place for the additional 200 L system up to the second half of 2020.”

This additional processing capability ensures that we have the necessary infrastructure in place to handle larger batch volumes for our customers.

We are growing quickly and are now in a position to service a broader customer base for later-stage clinical trials and will continue to invest in the technology and equipment needed to meet our customers’ requirements.

This latest expansion follows the company’s previous addition of an automatic filling line to extend its aseptic fill and finish capability and reinforce its ability to support early phase biologic supply needs for Phase I and II clinical trials.

With its facility in Cuxhaven, Germany, Vibalogics has been providing process development and GMP manufacturing services since 2002 and is recognized as a leading CDMO within the virotherapy development and manufacturing sector.

Ends

For further information, images and interview opportunities, please contact Eleanor Harms at ramarketing: eleanor@ramarketingpr.com | +44 (0)191 222 1242 | ramarketingpr.com | Twitter: @ramarketingpr | Facebook: /ramarketingpr | Linkedin: /ramarketing

Vibalogics GmbH
Zeppelinstraße 2
27472 Cuxhaven
Germany
+49 4721 565 400
contact@vibalogics.com

We’re the ideal CDMO for your Virotherapy project

Get in touch

SERVICE OFFERING

Looking for something different?

Vibalogics can assist you through a comprehensive service portfolio – ensuring success of your virotherapy, beginning with process development and technical transfer feasibility, through cGMP production and validation.

Related

What to read next

Vibalogics Completes Major Milestone in $5…

Vibalogics' expansion will provide added capacity and scalable clinical solutions for virotherapy ma…

The Medicine Maker: A New Focus for Cancer…

The Medicine Maker recently featured Joe Sinclair, Vice President, Business Development & Corporat…

GMP Manufacturing of Oncolytic Viruses: Cr…

The oncolytic virus (OV) sector needs to overcome several challenges to bring transformative cancer th…